C07D 211/88
Attached in positions 2 and 6
Official title: attached in positions 2 and 6, e.g. glutarimide
C07D211/88 (Attached in positions 2 and 6) appears on 238 US grants and 161 published applications in this corpus.
Search patents in C07D- Granted patents
- 238
- Published applications
- 161
- Assignees
- 118
- Inventors
- 531
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 5 | 0 |
| 1977 | 8 | 0 |
| 1978 | 4 | 0 |
| 1979 | 2 | 0 |
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 3 | 0 |
| 1983 | 5 | 0 |
| 1984 | 5 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 5 | 0 |
| 1991 | 4 | 0 |
| 1992 | 7 | 0 |
| 1993 | 6 | 0 |
| 1994 | 4 | 0 |
| 1995 | 7 | 0 |
| 1996 | 4 | 0 |
| 1997 | 8 | 0 |
| 1998 | 8 | 0 |
| 1999 | 4 | 0 |
| 2000 | 11 | 0 |
| 2001 | 5 | 0 |
| 2002 | 13 | 5 |
| 2003 | 4 | 8 |
| 2004 | 5 | 9 |
| 2005 | 5 | 8 |
| 2006 | 2 | 7 |
| 2007 | 6 | 7 |
| 2008 | 5 | 4 |
| 2009 | 2 | 5 |
| 2010 | 2 | 1 |
| 2011 | 2 | 4 |
| 2012 | 0 | 1 |
| 2013 | 3 | 7 |
| 2014 | 3 | 4 |
| 2015 | 8 | 3 |
| 2016 | 3 | 5 |
| 2017 | 4 | 7 |
| 2018 | 4 | 10 |
| 2019 | 6 | 10 |
| 2020 | 9 | 11 |
| 2021 | 13 | 5 |
| 2022 | 8 | 8 |
| 2023 | 3 | 10 |
| 2024 | 9 | 8 |
| 2025 | 3 | 11 |
| 2026 | 4 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- C3-carbon linked glutarimide Degronimers for target protein degradation21 Apr 2026US 12,605,450 B2C4 Therapeutics, Inc.
- Degraders and degrons for targeted protein degradation10 Mar 2026US 12,570,626 B2C4 Therapeutics, Inc.
- Small molecules against cereblon to enhance effector T cell function3 Mar 2026US 12,564,583 B2Lee Moffitt Cancer Center and Research Institute, Inc.
- CRBN ligands and uses thereof3 Feb 2026US 12,540,127 B2Kymera Therapeutics, Inc.
- Targeted protein degradation4 Nov 2025US 12,459,920 B2Monte Rosa Therapeutics AG
- Estrogen-receptor modulator and use thereof8 Oct 2026US 2026/0308139 A1Jiangsu Vcare PharmaTech Co., Ltd.
- Degraders and degrons for targeted protein degradation2 Jul 2026US 2026/0184688 A1C4 Therapeutics, Inc.
- N/o-linked degrons and degronimers for protein degradation15 Jan 2026US 2026/0015362 A1C4 Therapeutics, Inc.
- Estrogen receptor alpha degraders and methods of use thereof25 Dec 2025US 2025/0388565 A1Relay Therapeutics, Inc.
- Substance for promoting regeneration and repair of organs of mammals and use thereof4 Dec 2025US 2025/0367183 A1Beijing Institute for Stem Cell and Regenerative Medicine
Most cited
By later US patents
- Cyclic amides171US 5,698,579 ACelgene Corporation · 1997
- Cyclic amides169US 5,877,200 ACelgene Corporation · 1999
- Benzothiepin derivatives, process for the preparation of the same and uses thereof72US 6,355,672 B1Takeda Chemical Industries, Ltd. · 2002
- Benzisothiazole and benzisoxazole piperazine derivatives70US 4,411,901 AMead Johnson & Company · 1983
- Imides65US 5,605,914 ACelgene Corporation · 1997